Euclidean Capital LLC - Q1 2021 holdings

$299 Million is the total value of Euclidean Capital LLC's 13 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was - .

 Value Shares↓ Weighting
BEAM NewBEAM THERAPEUTICS INC$2,492,00031,131
+100.0%
0.83%
VIR NewVIR BIOTECHNOLOGY INC$1,326,00025,864
+100.0%
0.44%
PDD NewPINDUODUO INCsponsored ads$1,094,0008,174
+100.0%
0.37%
RUBY NewRUBIUS THERAPEUTICS INC$339,00012,791
+100.0%
0.11%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-05-17
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
PMV PHARMACEUTICALS INC12Q3 202354.4%
FOGHORN THERAPEUTICS INC12Q3 202316.4%
NGM BIOPHARMACEUTICALS INC12Q3 202314.5%
ALECTOR INC12Q3 202311.5%
RAPT THERAPEUTICS INC12Q3 20239.7%
ORIC PHARMACEUTICALS INC12Q3 202310.0%
TENAYA THERAPEUTICS INC9Q3 20239.9%
FIRST FINL BANCORP OH9Q4 20223.9%
SURROZEN INC9Q3 20232.9%
23ANDME HOLDING CO7Q3 202327.2%

View Euclidean Capital LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Euclidean Capital LLC Q1 2021 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
PMV Pharmaceuticals, Inc.February 14, 20222,336,9095.1%

View Euclidean Capital LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-02-14
13F-HR/A2023-12-01
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR2023-05-15
13F-HR2023-02-14
13F-HR2022-11-14
13F-HR2022-08-15
13F-HR2022-05-16
13F-HR2022-02-14

View Euclidean Capital LLC's complete filings history.

Compare quarters

Export Euclidean Capital LLC's holdings